user

MorphoSys’s Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019

Ventura Cannabis (VCAN) Continues to Execute on Cannabis Revenue Growth Strategy with a Dispensary and Delivery License in Sacramento; Posts Audited Annual Financial Statements (Ending February 28, 2019) For BLVD Centers; Appoints Jacob Gamble as Chairman

error: Content is protected !!